| Ytd | -22.66% | |
| 1y | -71.76% |
| Open | 1.54 | Prev Close | 1.51 | Low | 1.48 | High | 1.57 | Mkt Cap | 1.27M |
| Vol | 21.78K | Avg Vol | 88.68K | EPS | -6.86 | P/E | -0.23 | Forward P/E | -0.65 |
| Beta | 2.47 | Short Ratio | 0.34 | Inst. Own | 1.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 1.53 | 200-d Avg | 2.93 | 1yr Est | 3.40 |
SXTP News
License expands collaboration with Florida State University to evaluate castanospermine for Powassan
60 Degrees Pharma (Nasdaq: SXTP) secures exclusive option to develop castanospermine for tick-borne
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) ("60 Degrees Pharma" or the "Com
WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW
License allows the Company to commence large-scale extraction of castanospermine from the seeds of
Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Mi
WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTP
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP - Get Free Report) was the target of a significant dec
60 Degrees Pharmaceuticals Inc. (SXTP) might move higher on growing optimism about its earnings pros
FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after rais
60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsul
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are down during Friday's premarket session. Th
All three patients in 60 Degrees Pharma's expanded access study were cured of relapsing babesiosis a
Rafael (NYSE: RFL - Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ: SXTP - Get Free Report)
GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine) Collaboration designed
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are set to reverse split on the morning of Tue
WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (
Peer-reviewed NC State study found Babesia in 24% of chronic fatigue patients, supporting further st
60 Degrees Pharmaceuticals Inc. (SXTP) witnesses a hammer chart pattern, indicating support found by
60 Degrees Pharmaceuticals will expand ARAKODA sales in 2026 with more reps, a GoodRx partnership, e
60 Degrees Pharma opens enrollment at Mount Sinai for its B-FREE trial testing tafenoquine in chroni
During the session on Thursday, 461 stocks hit new 52-week lows.